117 related articles for article (PubMed ID: 10479512)
1. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer.
Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512
[TBL] [Abstract][Full Text] [Related]
2. p53 as a prognostic indicator in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141
[TBL] [Abstract][Full Text] [Related]
3. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
4. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
[TBL] [Abstract][Full Text] [Related]
5. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
6. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
7. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma.
Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
Gynecol Oncol; 1998 Nov; 71(2):305-7. PubMed ID: 9826476
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.
Hamel NW; Sebo TJ; Wilson TO; Keeney GL; Roche PC; Suman VJ; Hu TC; Podratz KC
Gynecol Oncol; 1996 Aug; 62(2):192-8. PubMed ID: 8751548
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
10. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
11. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
12. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
Salvesen HB; Das S; Akslen LA
Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
[TBL] [Abstract][Full Text] [Related]
13. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
[TBL] [Abstract][Full Text] [Related]
14. [Multivariate analysis of prognostic factors in endometrial carcinoma].
Li B; Wu LY; Li SM; Zhang WH; Zhang R; Ma SK
Ai Zheng; 2004 Sep; 23(9):1085-8. PubMed ID: 15363208
[TBL] [Abstract][Full Text] [Related]
15. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
16. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.
Lim P; Al Kushi A; Gilks B; Wong F; Aquino-Parsons C
Cancer; 2001 Feb; 91(4):752-7. PubMed ID: 11241243
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
19. A study of heat shock protein 27 in endometrial carcinoma.
Geisler JP; Geisler HE; Tammela J; Miller GA; Wiemann MC; Zhou Z
Gynecol Oncol; 1999 Mar; 72(3):347-50. PubMed ID: 10053106
[TBL] [Abstract][Full Text] [Related]
20. p53 and HER-2/neu overexpression in ovarian borderline tumors.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
